Significant Drop in Meloxicam Price Yields MSA Reductions
Posted on March 11, 2020 by Tower MSA Partners
The price of the non-steroidal anti-inflammatory (NSAID) Meloxicam took a major nosedive from $2.78 per pill to $0.05 per pill for 7.5 mg and $4.25 to $0.05 for 15 mg. Meloxicam (Brand name: Mobic) is commonly used to treat osteoarthritic pain and is frequently allocated in WC claims and MSAs. This is the medication’s first price reduction in more than a decade.
Tower will contact our clients to report any non-CMS-approved MSAs where we identify an allocation for Meloxicam and qualify for a revision. You can also contact us immediately to determine whether a particular MSA qualifies for a reduction. Revisions to the MSA can be done now or prior to MSA submission to CMS, if needed.
Please contact Dan Anders at Daniel.email@example.com or (888) 331-4941 with questions.
For Media Inquires, Contact:
Helen King Patterson
Search our blog:
Contact Us for a FREE Consultation